This study is designed to evaluate the efficacy and safety of zasocitinib in people living with Hidradenitis Suppurativa. Hidradenitis Suppurativa is a long-term skin condition that causes painful lumps, abscesses (pus-filled bumps), and inflammatory nodules (red, swollen lumps under the skin) to form, typically in areas where skin rubs together. The study focuses on individuals experiencing moderate to severe symptoms of this condition.

Participants in this trial will be assigned to receive either the study drug, zasocitinib, which is taken in the form of an oral capsule, or a placebo. This is a double-blind study, meaning that neither the participants nor the researchers will know which treatment is being administered until the study is completed. This method is used to ensure that the results are not influenced by expectations or biases.

During the course of the study, the progress of the condition will be monitored over several weeks. The main goal is to see how well the medication reduces the number of painful lumps and skin lesions compared to the placebo. The study will also track any adverse events, which are unintended medical problems or side effects that may occur during the treatment period.